Abstract
The prevalence of diabetes in the United States is rising. As HIV-infected people live longer, they become more susceptible to chronic diseases such as diabetes. Additionally, some antiretroviral agents have been linked to impaired glucose tolerance and increased diabetes risk. To estimate the burden and trends of diabetes among hospitalized HIV-infected persons in the United States, we used data from the 1994-2004 Nationwide Inpatient Sample, a nationally representative survey of inpatient hospitalizations. Odds ratios (OR) and 95% confidence intervals (CI) were adjusted for demographic and hospital characteristics using logistic regression. Between 1994 and 2004, the rate of hospitalizations with a diabetes code per 100 hospitalizations increased from 3.9 to 8.4 (2.2 fold) among HIV-infected persons. Among HIV-uninfected people, the corresponding rate increased from 12.8 to 17.7 (1.4 fold). Since 1998, the mean age of HIVinfected hospitalized people with a diabetes diagnosis rose from 45 to 66 years and became similar to that of HIVuninfected people. Compared to 1994-1996, in 2002-2004 the probability of hospitalizations with diabetes increased among both HIV-infected and HIV-uninfected persons (OR, 1.92, 95% CI, 1.79-2.05 and OR, 1.38, 95% CI, 1.36-1.40, respectively). Given the increasing prevalence of diabetes in hospitalized HIV-infected persons, it will be important to monitor the trends closely in addition to the effects of different types of antiretroviral regimens, in order to optimize comprehensive long-term care of HIV-infected persons.
Keywords: Diabetes, HIV infection, Hospitalizations, United States, Trends
Current HIV Research
Title: Diabetes Trends in Hospitalized HIV-Infected Persons in the United States, 1994-2004
Volume: 7 Issue: 5
Author(s): Athena P. Kourtis, Pooja Bansil, Henry S. Kahn, Samuel F. Posner and Denise J. Jamieson
Affiliation:
Keywords: Diabetes, HIV infection, Hospitalizations, United States, Trends
Abstract: The prevalence of diabetes in the United States is rising. As HIV-infected people live longer, they become more susceptible to chronic diseases such as diabetes. Additionally, some antiretroviral agents have been linked to impaired glucose tolerance and increased diabetes risk. To estimate the burden and trends of diabetes among hospitalized HIV-infected persons in the United States, we used data from the 1994-2004 Nationwide Inpatient Sample, a nationally representative survey of inpatient hospitalizations. Odds ratios (OR) and 95% confidence intervals (CI) were adjusted for demographic and hospital characteristics using logistic regression. Between 1994 and 2004, the rate of hospitalizations with a diabetes code per 100 hospitalizations increased from 3.9 to 8.4 (2.2 fold) among HIV-infected persons. Among HIV-uninfected people, the corresponding rate increased from 12.8 to 17.7 (1.4 fold). Since 1998, the mean age of HIVinfected hospitalized people with a diabetes diagnosis rose from 45 to 66 years and became similar to that of HIVuninfected people. Compared to 1994-1996, in 2002-2004 the probability of hospitalizations with diabetes increased among both HIV-infected and HIV-uninfected persons (OR, 1.92, 95% CI, 1.79-2.05 and OR, 1.38, 95% CI, 1.36-1.40, respectively). Given the increasing prevalence of diabetes in hospitalized HIV-infected persons, it will be important to monitor the trends closely in addition to the effects of different types of antiretroviral regimens, in order to optimize comprehensive long-term care of HIV-infected persons.
Export Options
About this article
Cite this article as:
Kourtis P. Athena, Bansil Pooja, Kahn S. Henry, Posner F. Samuel and Jamieson J. Denise, Diabetes Trends in Hospitalized HIV-Infected Persons in the United States, 1994-2004, Current HIV Research 2009; 7 (5) . https://dx.doi.org/10.2174/157016209789346228
DOI https://dx.doi.org/10.2174/157016209789346228 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Use of Chou’s 5-steps Rule to Study the Effect of Cereal Dietary Protein on Liver and Coronary Heart Disease Prevention
Current Nutrition & Food Science HDL Elevators and Mimetics - Emerging Therapies for Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Levosimendan Preoperative
Current Pharmaceutical Design Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science TSH Variations in Chronic Heart Failure Outpatients: Clinical Correlates and Outcomes
Endocrine, Metabolic & Immune Disorders - Drug Targets Muscarinic Acetylcholine Receptors
Current Pharmaceutical Design Molecular Mechanisms of Inherited Arrhythmias
Current Genomics Cardiovascular Risk in Perimenopausal Women
Current Vascular Pharmacology Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors
CNS & Neurological Disorders - Drug Targets Diabetic Nephropathy: Pathogenesis to Cure
Current Drug Targets On the Paradigm Shift Towards Multitarget Selective Drug Design
Current Computer-Aided Drug Design Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine Pharmacological Therapies for Pediatric and Neonatal ALI/ARDS: An Evidence-Based Review
Current Drug Targets Aging Eye Microbiota in Dry Eye Syndrome in Patients Treated with Enterococcus faecium and Saccharomyces boulardii
Current Clinical Pharmacology Tissue Engineering for Post-Myocardial Infarction Ventricular Remodeling
Mini-Reviews in Medicinal Chemistry Drug-Induced Pulmonary Hypertension in Newborns: A Review.
Current Vascular Pharmacology A Proteomic Analysis of the Virulence Factors of Three Common Bacterial Species Involved in Periodontitis and Consequent Possible Atherosclerosis: A Narrative Review
Current Protein & Peptide Science Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design